Jubilant Pharmova Ltd logo

Jubilant Pharmova Ltd

JUBLPHARMA NSE

Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]

AI Verdict: HOLD Confidence: 5%

Jubilant Pharmova trades at a PE of 38.7x with weak 3-year ROE of 6% and poor 5-year sales CAGR of 6%, making valuation hard to justify. However, 75% analyst buy ratings, improving working capital (reduced from 28.6 to 13.4 days), and strong 3-year profit CAGR of 47% suggest a turnaround in progress that warrants monitoring rather than immediate action.

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹15,491 Cr
Volatility
Moderate
P/E Ratio
38.55
EBITDA
₹1,146 Cr
Return on Equity
1.34%
Debt to Equity
0.55
Book Value
₹445.26
EPS
₹14.96
52W High
₹1,248
52W Low
₹786.05

Technical Indicators

Key Insights

Strengths

2
  • Company has been maintaining a healthy dividend payout of 43.9%
  • Company's working capital requirements have reduced from 28.6 days to 13.4 days

Weaknesses

4
  • The company has delivered a poor sales growth of 6.31% over past five years.
  • Company has a low return on equity of 5.80% over last 3 years.
  • Company might be capitalizing the interest cost
  • Promoter holding has decreased over last 3 years: -3.01%

Growth Rate

Revenue Growth
12.81% ↗
Net Income Growth
-45.79% ↘
Cash Flow Change
10.38% ↗
ROE
900.75% ↗
ROCE
151.75% ↗
EBITDA Margin (Avg.)
-18.13% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
HOLD
Risk high

Jubilant Pharmova trades at a PE of 38.7x with weak 3-year ROE of 6% and poor 5-year sales CAGR of 6%, making valuation hard to justify. However, 75% analyst buy ratings, improving working capital (reduced from 28.6 to 13.4 days), and strong 3-year profit CAGR of 47% suggest a turnaround in progress that warrants monitoring rather than immediate action.

Bull Case 7
  • 75% of analysts (3 out of 4) rate the stock a Buy, indicating institutional confidence in the turnaround thesis
  • 3-year compounded profit CAGR of 47% shows strong earnings recovery from the trough
  • Working capital days reduced sharply from 28.6 days to 13.4 days, indicating improved operational efficiency and cash conversion
  • Healthy dividend payout ratio of 43.9% demonstrates management commitment to returning capital to shareholders
  • TTM sales growth of 14% is a meaningful acceleration versus the 5-year CAGR of 6%, suggesting improving demand trajectory
  • 10-year stock CAGR of 13% shows long-term wealth creation track record despite recent weakness
  • 10-year ROE of 10% indicates the business has historically earned reasonable returns on equity when operating at scale
Bear Case 8
  • PE of 38.7x is elevated for a company delivering only 6% ROE over the last 3 years, implying expensive valuation relative to returns
  • 5-year compounded profit CAGR is negative at -13%, indicating sustained earnings destruction over a medium-term horizon
  • 5-year sales CAGR of just 6.31% reflects structurally poor topline growth for a mid-cap pharma company
  • Stock has declined 13% over the past 1 year, underperforming broader market indices significantly
  • Promoter holding has decreased by 3.01% over the last 3 years, signaling potential lack of promoter confidence
  • 3-year ROE of only 6% is well below cost of equity, meaning the company is destroying shareholder value on a risk-adjusted basis
  • TTM profit growth is negative at -22%, suggesting the recent recovery may already be reversing
  • Company might be capitalizing interest costs, which could overstate reported profitability and asset quality

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 1d ago
Headwinds 1
  • Eight USFDA observations at Spokane Jun 18

    USFDA concluded inspection at Jubilant Pharmova's Spokane facility on June 17, 2026, issuing eight observations. While unrelated to sterility, multiple observations signal regulatory remediation work ahead.

Neutral 1
  • USFDA Spokane inspection concludes Jun 18

    USFDA inspection at the Spokane facility concluded on June 17, 2026, with eight observations all unrelated to sterility, suggesting core manufacturing processes remain intact.

TL;DR: Jubilant Pharmova faces a near-term regulatory overhang after receiving eight USFDA observations at its Spokane facility, though the fact that none relate to sterility is a modest relief. The company will need to submit a corrective action plan, and investors will watch for a satisfactory resolution. No positive catalysts emerged this period. The trend is cautiously neutral pending the FDA response outcome.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
1,678
1,587
1,680
1,677
1,759
1,732
1,752
1,822
1,929
1,901
1,966
2,122
2,290
Expenses
1,459
1,419
1,438
1,459
1,487
1,480
1,463
1,535
1,584
1,611
1,625
1,833
1,951
Operating Profit
219
168
242
218
271
252
289
287
345
290
341
289
339
OPM %
13%
11%
14%
13%
15%
15%
17%
16%
18%
15%
17%
14%
15%
Other Income
21
9
19
49
-151
410
8
-10
9
12
4
-19
10
Interest
56
62
66
71
73
71
61
56
53
49
50
56
56
Depreciation
271
90
97
95
101
91
91
91
95
98
105
121
117
PBT
-86
25
98
101
-54
500
144
130
206
154
190
93
176
Tax %
16%
76%
37%
34%
15%
4%
29%
23%
27%
34%
37%
40%
32%
Net Profit
-100
6
62
66
-62
482
102
101
151
102
120
56
119
EPS in Rs
-6.15
0.4
3.92
4.19
-3.68
30.26
6.45
6.33
9.64
6.46
7.55
3.51
7.5
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
5,751
5,749
5,861
7,518
9,111
5,976
6,099
6,130
6,282
6,703
7,234
8,280
Expenses
5,141
4,493
4,510
5,995
7,367
4,428
4,695
4,980
5,503
5,802
6,061
7,020
Operating Profit
610
1,256
1,352
1,522
1,744
1,548
1,403
1,150
779
901
1,173
1,260
OPM %
11%
22%
23%
20%
19%
26%
23%
19%
12%
13%
16%
15%
Other Income
86
4
19
36
-249
225
263
8
-9
-76
416
7
Interest
368
371
341
284
220
200
184
145
188
272
240
212
Depreciation
288
347
291
415
371
340
349
382
554
382
369
440
PBT
40
542
738
859
904
1,233
1,133
630
28
170
981
614
Tax %
200%
29%
22%
26%
36%
27%
26%
34%
333%
57%
15%
35%
Net Profit
-40
387
575
634
577
898
836
413
-65
73
836
398
EPS in Rs
-3.63
24.6
36.14
40.35
36.06
56.39
52.47
25.98
-3.83
4.84
52.69
25.02
Div. Payout %
-83%
12%
8%
7%
12%
9%
10%
19%
-130%
102%
9%
20%
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
16
16
16
16
16
16
16
16
16
16
16
16
Reserves
2,438
2,951
3,420
4,071
4,793
5,588
4,726
5,303
5,383
5,418
6,239
7,077
Borrowings
4,793
4,493
4,045
3,469
4,840
4,808
2,830
3,192
3,677
3,664
2,731
3,615
Other Liabilities
1,372
1,280
1,417
1,902
1,670
1,898
1,192
1,319
1,853
2,240
3,598
4,815
Total Liabilities
8,619
8,740
8,899
9,457
11,319
12,310
8,763
9,830
10,929
11,338
12,584
15,523
Fixed Assets
4,911
5,104
5,107
5,401
5,648
6,340
4,609
4,871
5,183
5,091
5,176
8,044
CWIP
597
611
684
671
901
768
897
1,090
1,562
2,103
3,630
2,962
Investments
40
85
103
124
115
69
241
239
256
42
44
61
Other Assets
3,071
2,939
3,006
3,262
4,654
5,133
3,017
3,631
3,928
4,101
3,735
4,455
Total Assets
8,619
8,740
8,899
9,457
11,319
12,310
8,763
9,830
10,929
11,338
12,584
15,523
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
783
1,099
1,268
1,303
1,122
1,543
1,784
838
661
971
1,072
1,227
Investing
-362
-309
-465
-614
-1,018
-267
-727
-323
-474
-596
512
-1,260
Financing
-503
-843
-686
-901
657
-1,050
-1,709
-33
-157
-432
-1,453
95
Net Cash Flow
-82
-52
117
-212
761
225
-652
482
30
-58
132
62
Free Cash Flow
434
760
806
819
473
975
1,270
241
-135
83
-38
-120
CFO/OP
141
91
104
103
84
116
155
90
111
131
112
114
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
52
60
63
55
51
79
49
55
56
50
45
47
Inventory Days
169
207
223
177
147
463
268
308
268
220
178
170
Days Payable
99
106
137
145
106
273
124
139
160
146
158
170
Cash Conversion Cycle
122
162
149
87
92
268
194
224
165
124
65
47
Working Capital Days
12
4
50
45
45
62
74
56
57
56
16
13
ROCE %
6%
13%
15%
15%
16%
15%
12%
10%
3%
7%
10%
9%

Shareholding Pattern

As of Mar 2026
Promoters 47.68%
Public 17.57%
FIIs 15.90%
DIIs 11.62%
Others 7.23%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
47.68%
47.68%
47.68%
47.68%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
23.21%
0.00%
19.06%
19.49%
17.94%
16.96%
17.22%
17.40%
16.57%
15.96%
15.90%
DIIs
0.78%
1.15%
0.40%
0.43%
0.05%
0.04%
0.39%
1.62%
0.40%
1.63%
1.65%
1.50%
3.78%
4.07%
5.66%
6.98%
7.05%
9.53%
10.52%
11.22%
11.62%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
1.24%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
16.07%
16.98%
19.03%
18.97%
19.27%
19.35%
19.01%
18.68%
18.69%
18.25%
18.24%
18.76%
18.71%
17.79%
18.09%
18.09%
17.75%
17.97%
18.02%
17.85%
17.57%
Others
32.47%
31.19%
29.89%
29.92%
30.00%
29.93%
29.92%
29.02%
28.98%
29.44%
6.22%
29.06%
7.77%
7.97%
7.63%
7.30%
7.31%
7.42%
7.22%
7.29%
7.23%
No. of Shareholders
0
61,942
87,493
1,13,776
1,09,420
1,08,063
1,09,410
1,05,632
97,935
93,375
89,376
86,588
92,264
81,992
89,456
1,02,442
96,526
99,673
93,336
90,133
86,347

Documents

1
Concall - Aug 2017 Aug 2017
2
Concall - Jun 2018 Jun 2018
3
Concall - Mar 2022 Mar 2022
4
Concall - Nov 2022 Nov 2022
5
Concall - May 2023 May 2023

Frequently Asked Questions about Jubilant Pharmova Ltd

What does Jubilant Pharmova Ltd do?
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]
Where is Jubilant Pharmova Ltd (JUBLPHARMA) listed?
Jubilant Pharmova Ltd is listed on the Indian stock exchanges. It is listed on NSE: JUBLPHARMA and BSE: 530019. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Jubilant Pharmova Ltd belong to?
Jubilant Pharmova Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd has a market capitalisation of approximately ₹15490.89 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Jubilant Pharmova Ltd?
The Price-to-Earnings (PE) ratio of Jubilant Pharmova Ltd is 38.55. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Jubilant Pharmova Ltd?
Over the past 52 weeks, Jubilant Pharmova Ltd has traded between a low of ₹786.05 and a high of ₹1,248. This range helps investors understand the stock's price volatility and recent trading levels.
Does Jubilant Pharmova Ltd pay dividends?
Yes, Jubilant Pharmova Ltd has a dividend yield of 0.51%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd has a Return on Equity (ROE) of 1.34%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Jubilant Pharmova Ltd on Tapetide?
On Tapetide, you can view Jubilant Pharmova Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]

Website jubl.com
CEO Mr. Priyavrat Bhartia MBA
Employees 5,547
Listed 2003-06-16
Face Value ₹ 1
Issued Size 15,92,81,139

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List